Australia tentatively approves Pfizer boosters ages 16-17


Therapeutic Goods Administration, an Australian drug regulator, has tentatively approved the use of Pfizer’s COVID-19 vaccine as a booster shot for teens aged 16 and 17.

Dosages for this age group are the same as for adults, and booster immunizations can be given within 3-4 months of receiving the first two doses, regardless of the brand of the first two doses. ..

This decision follows Pfizer’s provisional approval to use the Community Vaccine for Pfizer as a booster for individuals over the age of 18 on October 26, 2021. Additional immune doses over 16 years of age are also approved for use in the United States. Israel, and England.

Health Minister Greg Hunt sunrise This was “good news”.

“This is the first of the two green lights we need. Our medical regulator, Therapeutic Goods Administration, states that Pfizer, aged 16-17 as a booster, is safe and effective.” Hunt said.

The Australian Technical Advisory Group on Immunity (ATAGI) is expected to soon provide advice and more information on when this age group is eligible to receive boosters.

“We hope to get advice from them as early as next week,” Hunt said, promising that boosters will be available soon after being approved by ATAGI.

The minister said the booster effect was “abnormal” at 232,000 times as of January 27.

“Two-thirds of the eligible population are already taking boosters, so in reality, boosters are being taken at a faster rate than the highest daily dose from the first or second dose. I understand, “he said.

He said people infected with the new coronavirus Omicron strain still need to get booster shots.

“It’s very clear medical advice from Australia’s Chief Medical Officer,” he said.

The TGA will continue to monitor ongoing trials related to booster immunization in infants.

According to the TGA, provisional approval of the vaccine is subject to certain stringent conditions, including the requirement that Pfizer continue to provide TGA with long-term efficacy and safety information from ongoing clinical trials and post-marketing assessments. increase.

Marina Chan

follow

Marina Chan is a Melbourne-based Australian reporter with a focus on Australian news. Contact her at [email protected]